Akero Therapeutics (NASDAQ:AKRO) Downgraded by Morgan Stanley to Equal Weight

Akero Therapeutics} stock has undergone multiple analysts rating changes in the recent past.  Akero Therapeutics Downgraded by Morgan Stanley on 10/19/2021. In a note to investors, the firm issued a new rating of Equal Weight. The analysts previously had rating of Overweight.

View More Akero Therapeutics (NASDAQ:AKRO) Downgraded by Morgan Stanley to Equal Weight

Akero Therapeutics (NASDAQ:AKRO) Downgraded by Zacks Investment Research to Sell

Akero Therapeutics} stock has undergone multiple analysts rating changes in the recent past.  Akero Therapeutics Downgraded by Zacks Investment Research on 10-12-21. In a note to investors, the firm issued a new rating of Sell. The analysts previously had rating of Hold.

View More Akero Therapeutics (NASDAQ:AKRO) Downgraded by Zacks Investment Research to Sell

Is it time to Buy before this week’s earning report Akero Therapeutics (NASDAQ:AKRO)

Earnings results for Akero Therapeutics , Analyst Opinion on Akero Therapeutics , Earnings and Valuation of (NASDAQ:AKRO), Stock market Insights & financial analysis, Best stock to invest, Investment Idea,

View More Is it time to Buy before this week’s earning report Akero Therapeutics (NASDAQ:AKRO)

Will stock surge before Earnings results? Akero Therapeutics (NASDAQ:AKRO)

Earnings results for Akero Therapeutics , Analyst Opinion on Akero Therapeutics , Earnings and Valuation of (NASDAQ:AKRO), Stock market Insights & financial analysis, Best stock to invest, Investment Idea,

View More Will stock surge before Earnings results? Akero Therapeutics (NASDAQ:AKRO)

Reports Strong First-Quarter Financial Results Akero Therapeutics (NASDAQ:AKRO)

Earnings results for Akero Therapeutics , Analyst Opinion on Akero Therapeutics , Earnings and Valuation of (NASDAQ:AKRO), Stock market Insights & financial analysis, Best stock to invest, Investment Idea,

View More Reports Strong First-Quarter Financial Results Akero Therapeutics (NASDAQ:AKRO)